Members of the Assessment Panel of Incu-Bio Programme:

- 1. Mr. Alan AU, GT Healthcare Capital Partners
- 2. Dr. Alfa BAI, BGI Health (HK) Co. Ltd
- 3. Prof. Barbara CHAN, Department of Mechanical Engineering, The Hong Kong University of Hong Kong
- 4. Prof. Wai Yee CHAN, School of Biomedical Sciences, The Chinese University of Hong Kong
- 5. Prof. Lawrence CHAN, Department of Health Technology and Informatics, Hong Kong Polytechnic University
- 6. Mr. Benjamin CHAN, MediConcepts Limited
- 7. Prof. Danny CHAN, School of Biomedical Sciences, The University of Hong Kong
- 8. Prof. Danny CHAN, Department of Surgery, The Chinese University of Hong Kong
- 9. Dr. Raymond CHANG, School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong
- 10. Prof. Kathryn CHEAH, School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong
- 11. Prof. Hao CHEN, Department of Computer Science and Engineering, Hong Kong University of Science and Technology
- 12. Dr. Jingxian CHEN, GuangZhou KingMed Diagnostics Group Co., Ltd
- 13. Mr. Chandler CHEN, I-Campus Director, AstraZeneca China
- 14. Ms. Yating CHENG, Guangzhou KingMed Diagnostic Group Co Ltd
- 15. Prof. Tom H. CHEUNG, Division of Life Science, Hong Kong University of Science and Technology
- 16. Prof. Yiu Fai CHEUNG, Department of Paediatrics and Adolescent Medicine, The University of Hong Kong
- 17. Prof. Philip CHIU, Department of Surgery, The Chinese University of Hong Kong
- 18. Dr. William CHO, Department of Clinical Oncology, Queen Elizabeth Hospital
- 19. Dr. Long CUI, Director of Reproductive Health, Guangzhou KingMed Diagnostics Group Co., LTD
- 20. Dr. Abby GAO, DEFTA Partners
- 21. Prof. Yi-Ke GUO, Research and Development, Hong Kong Baptist University
- 22. Ms. Martha HAO, Hong Kong Medical & Healthcare Device Industries Association
- 23. Dr. Mia HU, Boehringer Ingelheim Venture Fund
- 24. Prof. David HUI, Department of Medicine and Therapeutics, The Chinese University of Hong Kong
- 25. Mr. Marcus HUI, GT Healthcare Capital Partners
- 26. Prof. Wei JIA, School of Chinese Medicine, Hong Kong Baptist University

- 27. Prof. Liwen JIANG, School of Life Sciences, The Chinese University of Hong Kong
- 28. Dr. Clinton LAI, Translational Clinical Oncology, Novartis Institutes for Biomedical Research
- 29. Mr. Adrian Lam, Bioworld Ventures Limited
- 30. Prof. Hon Ming LAM, School of Life Sciences, The Chinese University of Hong Kong
- 31. Dr. Patrick LAM, Hong Kong Exchange and Clearing Limited
- 32. Prof. Clara Bik-San LAU, Institute of Chinese Medicine, The Chinese University of Hong Kong
- 33. Mr. Sampson LAU, PrimaNova Lab (Shenzhen) Limited
- 34. Dr. Chi Ming LEE, School of Life Sciences, The Chinese University of Hong Kong
- 35. Prof. Christopher LEUNG, Department of Ophthalmology, The University of Hong Kong
- 36. Dr. Shawn LEUNG, SinoMab BioScience Limited
- 37. Prof. Albert LI, Department of Paediatrics, The Chinese University of Hong Kong
- 38. Dr. Chris LI, Janssen Biopharma, Inc, Johnson & Johnson
- 39. Ms. Suyu LI, New World Strategic Investment Limited
- 40. Mr. Yinghua LI, Guangzhou KingMed Diagnostic Group Co Ltd
- 41. Dr. Qizhou LIAN, Department of Ophthalmology, The University of Hong Kong
- 42. Prof. Zhixiu LIN, School of Chinese Medicine, The Chinese University of Hong Kong
- 43. Prof. William LU, Department of Orthopaedics and Traumatology, The University of Hong Kong
- 44. Dr. Pifu LUO, Department of Pathology, Guangzhou KingMed Diagnostic Group Co Ltd
- 45. Dr. Jun MAO, VVBI Limited
- 46. Dr. Matthew MAN, Megasoft Limited
- 47. Dr. Temy Mo Yin MOK, Department of Biomedical Sciences, City University of Hong Kong
- 48. Ms. Carol MUI, Executive Director, Oncology, AstraZeneca Hong Kong Limited
- 49. Mr. Jianhua PAN, Hematology/Flow cytometry Department, Guangzhou KingMed Diagnostic Group Co Ltd
- 50. Prof. Stella PANG, Department of Electronic Engineering, City University of Hong Kong
- 51. Dr. Qing PENG, Northern Light Venture Capital
- 52. Mr. Jiankang REN, Guangzhou KingMed Diagnostic Group Co Ltd
- 53. Dr. Qiusong TANG, Roche Accelerator
- 54. Prof. Raymond TONG, Department of Biomedical Engineering, The Chinese University of Hong Kong
- 55. Dr. Thomas ROSCHKE, Johnson Medtech, Murten

- 56. Prof. Ding-Ping TSAI, Department of Electrical Engineering, City University of Hong Kong
- 57. Dr. Albert TSAI, Zhaoke Ophthalmology Limited
- 58. Prof. Karl TSIM, Division of Life Science, The Hong Kong University of Science and Technology
- 59. Prof. Kelvin TSOI, JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong
- 60. Dr. Bill WONG, Sirnaomics
- 61. Prof. Kenneth WONG, Department of Electrical and Electronic Engineering, The University of Hong Kong
- 62. Prof. Rick WONG, Department of Chemistry, Hong Kong Baptist University
- 63. Prof. Wing Tak WONG, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University
- 64. Prof. Yung Hou WONG, Dean of Science (Research, Graduate Studies & Administration), Hong Kong University of Science and Technology
- 65. Dr. Stephen WU, Former Head of College of Life Sciences and Technology, The University of Hong Kong
- 66. Prof. Aimin XU, Department of Pharmacology and Pharmacy, The University of Hong Kong
- 67. Mr. Henry YAM, IDS Medical Systems Group
- 68. Dr. WC YAM, Department of Microbiology, The University of Hong Kong
- 69. Mr. Stephen YUEN, 18 Salisbury Capital
- 70. Prof. Shihui YU, Guangzhou KingMed Diagnostic Group Co Ltd
- 71. Prof. Benny Chung Ying ZEE, Office of Research and Knowledge Transfer Services, The Chinese University of Hong Kong
- 72. Dr. Hua ZHANG, SPH Biotherapeutics (HK) limited
- 73. Dr. Weiyi ZHANG, Boehringer Ingelheim Venture Fund
- 74. Prof. Yuanting Zhang, Hong Kong Center for Cerebro-cardiovascular Health Engineering

The above list is subject to change without notice, please contact Incubio Team for the most updated list.

With strong and justified reason(s), an Applicant can opt-out member(s) of the Assessment Panel. Such request must be given in writing and submitted together with the application (late request will not be accepted), and HKSTP reserves the right of final decision in case of any disputes.